North America Early Toxicity Testing Market by Technique (In Vivo, In Vitro, and In Silico), by Toxicity Endpoint (Genotoxicity, Dermal Toxicity, Skin Toxicity, Ocular Toxicity, Phototoxicity, and Others), by End User (Pharmaceutical Industry, Cosmetic Industry, Chemical Industry, Food Industry, and Others) – Opportunity Analysis and Industry Forecast, 2023-2030

North America Early Toxicity Testing Market

Industry:  Life Sciences & Healthcare | Publish Date: Aug 2023 | No of Pages:  110 | No. Tables:  96 | No. Figures:  45

Market Definition

North Early Toxicity Testing Market was valued at USD 2.48 billion in 2022, and is predicted to reach USD 4.30 billion by 2030, with a CAGR of 6.15% from 2023 to 2030.

Early toxicity testing is a process that involves evaluating the potential toxicity or adverse effects of drugs, chemicals, or other substances at an early stage of development, typically in vitro or in animal models, before they are tested in humans. The goal of early toxicity testing is to identify any potential safety concerns with a substance and determine whether it is safe to proceed with further development and testing.

Early toxicity testing helps to reduce the risk of harm to humans and animals during clinical trials and reduce cost and time of drug development. Early toxicity testing typically involves a range of tests and assays, such as cell viability assays, genotoxicity assays, and pharmacokinetic studies. Specific tests and methods used depend on the nature of substance being tested and intended use of the product. Early toxicity testing is an important step in drug development process that helps to ensure safety and efficacy of new drugs and other substances before they are approved for use in humans.

Prominent Pharmaceutical Landscape in North America Fuels Demand for Advanced Early Toxicity Testing Methods

The North American region comprises the United States, Canada, and Mexico, and it benefits from the significant presence of leading pharmaceutical firms. This substantial industry presence enables substantial investments in the advancement of novel drugs and treatments. As research and development efforts continue to expand within this area, there is a notable requirement for effective and trustworthy methods of conducting preliminary toxicity testing. These methods are crucial for detecting and resolving potential safety concerns prior to embarking on human trials. 

For instance, the U.S. increased its medical and health research & development (R&D) spending to USD 245.1 billion in 2021, primarily for drug discovery and development for urgent medical needs such as cancer, neurodegenerative diseases, and rare genetic disorders.

 

Pioneering Personalized Medicine: A Catalyst for Advancing Early Toxicity Testing in North America

The North American healthcare landscape stands as a vibrant hub of innovation and progress, and a particularly compelling force driving this dynamism is the escalating demand for personalized medicine. Within this context, the burgeoning interest in tailored treatment options has not only redefined patient care but also become a central impetus propelling the growth of the early toxicity testing market. The region's distinctive position at the forefront of advancing healthcare practices, coupled with its fervent embrace of personalized medicine, underscores the intricate interplay between patient-centricity, scientific advancement, and the critical need for early toxicity testing to ensure optimal patient outcomes.

 

Regulatory Constraints and their Impact on Early Toxicity Testing Market Growth in North America

However, stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing. As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services. Moreover, stringent regulations can also result in a lengthy approval process for new drugs, further delaying the time it takes for drugs to reach the market. This, in turn, is expected to hamper growth of the market.

Technological Advancements in the field of Early Toxicity Testing Market in North America

Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period. Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing. However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. 3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.

 

Competitive Landscape  

The North America Early Toxicity Testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG. and Thermo Fisher Scientific Inc.

KEY BENEFITS

  • The North America Early Toxicity Testing market report provides a quantitative analysis of the current market and estimations through 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.

  • The study comprises a deep dive analysis of the market trend including the current and future trends for depicting the prevalent investment pockets in the market.

  • The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.

  • The competitive analysis of the market players along with their market share in the North America Early Toxicity Testing market.

  • The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

  • Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

NORTH AMERICA EARLY TOXICITY TESTING MARKET KEY SEGMENTS

By Technique

  • In Vivo

  • In Vitro

    • Cell Culture    

    • PCR    

    • ELISA    

    • Western Blotting    

    • Protein Binding Assays    

  • In Silico    

By Toxicity Endpoint

  • Genotoxicity    

  • Dermal Toxicity 

  • Skin Toxicity 

  • Ocular Toxicity    

  • Phototoxicity    

  • Others    

By End User

  • Pharmaceutical Industry    

  • Cosmetic Industry    

  • Chemical Industry    

  • Food Industry     

  • Others        

By Geography

  • North America

    • U.S.

    • Canada

    • Mexico

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2022

USD 2.48 Billion

Revenue Forecast in 2030

USD 4.30 Billion

Growth Rate

CAGR of 6.15% from 2023 to 2030

Analysis Period

2022–2030

Base Year Considered

2022

Forecast Period

2023–2030

Market Size Estimation

Billion (USD)

Growth Factors

The presence of major pharmaceutical companies.

 

The demand for personalized medicine.

Countries Covered

3

Companies Profiled

15

Market Share

Available for 15 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2      NORTH AMERICA EARLY TOXICITY TESTING MARKET BY TECHNIQUE

           2.1      OVERVIEW

           2.2      IN VIVO

                         2.2.1      IN VIVO MARKET, BY COUNTRY

           2.3      IN VITRO

                         2.3.1      IN VITRO MARKET, BY TECHNIQUE

                                          2.3.1.1      CELL CULTURE MARKET, BY COUNTRY

                                          2.3.1.2      PCR MARKET, BY COUNTRY

                                          2.3.1.3      ELISA MARKET, BY COUNTRY

                                          2.3.1.4      WESTERN BLOTTING MARKET, BY COUNTRY

                                          2.3.1.5      PROTEIN BINDING ASSAYS  MARKET, BY COUNTRY

                         2.3.2      IN VITRO MARKET, BY COUNTRY

           2.4      IN SILICO

                         2.4.1      IN SILICO MARKET, BY COUNTRY

3      NORTH AMERICA EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT

           3.1      OVERVIEW

           3.2      GENOTOXICITY

                         3.2.1      GENOTOXICITY MARKET, BY COUNTRY

           3.3      DERMAL TOXICITY

                         3.3.1      DERMAL TOXICITY MARKET, BY COUNTRY

           3.4      SKIN TOXICITY

                         3.4.1      SKIN TOXICITY MARKET, BY COUNTRY

           3.5      OCULAR TOXICITY

                         3.5.1      OCULAR TOXICITY MARKET, BY COUNTRY

           3.6      PHOTOTOXICITY

                         3.6.1      PHOTOTOXICITY MARKET, BY COUNTRY

           3.7      OTHERS

                         3.7.1      OTHERS MARKET, BY COUNTRY

4      NORTH AMERICA EARLY TOXICITY TESTING MARKET BY END USER

           4.1      OVERVIEW

           4.2      PHARMACEUTICAL INDUSTRY

                         4.2.1      PHARMACEUTICAL INDUSTRY MARKET, BY COUNTRY

           4.3      COSMETIC INDUSTRY

                         4.3.1      COSMETIC INDUSTRY MARKET, BY COUNTRY

           4.4      CHEMICAL INDUSTRY

                         4.4.1      CHEMICAL INDUSTRY MARKET, BY COUNTRY

           4.5      FOOD INDUSTRY

                         4.5.1      FOOD INDUSTRY MARKET, BY COUNTRY

           4.6      OTHERS

                         4.6.1      OTHERS MARKET, BY COUNTRY

5      NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY

           5.1     OVERVIEW

           5.2     UNITED STATES

                         5.2.1     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.2.2     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.2.3     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER

           5.3     CANADA

                         5.3.1     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.3.2     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.3.3     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER

           5.4     MEXICO

                         5.4.1     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE

                         5.4.2     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINT

                         5.4.3     NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER

6      COMPANY PROFILES

           6.1   INOTIV INC.

                         6.1.1   COMPANY OVERVIEW

                         6.1.2   COMPANY SNAPSHOT

                         6.1.3   OPERATING BUSINESS SEGMENTS

                         6.1.4   PRODUCT PORTFOLIO

                         6.1.5   BUSINESS PERFORMANCE

                         6.1.6   BUSINESS SEGMENTS

                         6.1.7   GEOGRAPHIC SEGMENTS

                         6.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.1.9   PRIMARY MARKET COMPETITORS

           6.2   BIO-RAD LABORATORIES INC.

                         6.2.1   COMPANY OVERVIEW

                         6.2.2   COMPANY SNAPSHOT

                         6.2.3   OPERATING BUSINESS SEGMENTS

                         6.2.4   PRODUCT PORTFOLIO

                         6.2.5   BUSINESS PERFORMANCE

                         6.2.6   BUSINESS SEGMENTS

                         6.2.7   GEOGRAPHIC SEGMENTS

                         6.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.2.9   PRIMARY MARKET COMPETITORS

           6.3   EVOTEC A.G.

                         6.3.1   COMPANY OVERVIEW

                         6.3.2   COMPANY SNAPSHOT

                         6.3.3   OPERATING BUSINESS SEGMENTS

                         6.3.4   PRODUCT PORTFOLIO

                         6.3.5   BUSINESS PERFORMANCE

                         6.3.6   BUSINESS SEGMENTS

                         6.3.7   GEOGRAPHIC SEGMENTS

                         6.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.3.9   PRIMARY MARKET COMPETITORS

           6.4   AGILENT TECHNOLOGIES INC.

                         6.4.1   COMPANY OVERVIEW

                         6.4.2   COMPANY SNAPSHOT

                         6.4.3   OPERATING BUSINESS SEGMENTS

                         6.4.4   PRODUCT PORTFOLIO

                         6.4.5   BUSINESS PERFORMANCE

                         6.4.6   BUSINESS SEGMENTS

                         6.4.7   GEOGRAPHIC SEGMENTS

                         6.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.4.9   PRIMARY MARKET COMPETITORS

           6.5   WUXI APPTEC

                         6.5.1   COMPANY OVERVIEW

                         6.5.2   COMPANY SNAPSHOT

                         6.5.3   OPERATING BUSINESS SEGMENTS

                         6.5.4   PRODUCT PORTFOLIO

                         6.5.5   BUSINESS PERFORMANCE

                         6.5.6   BUSINESS SEGMENTS

                         6.5.7   GEOGRAPHIC SEGMENTS

                         6.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.5.9   PRIMARY MARKET COMPETITORS

           6.6   BRUKER

                         6.6.1   COMPANY OVERVIEW

                         6.6.2   COMPANY SNAPSHOT

                         6.6.3   OPERATING BUSINESS SEGMENTS

                         6.6.4   PRODUCT PORTFOLIO

                         6.6.5   BUSINESS PERFORMANCE

                         6.6.6   BUSINESS SEGMENTS

                         6.6.7   GEOGRAPHIC SEGMENTS

                         6.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.6.9   PRIMARY MARKET COMPETITORS

           6.7   PERKINELMER INC.

                         6.7.1   COMPANY OVERVIEW

                         6.7.2   COMPANY SNAPSHOT

                         6.7.3   OPERATING BUSINESS SEGMENTS

                         6.7.4   PRODUCT PORTFOLIO

                         6.7.5   BUSINESS PERFORMANCE

                         6.7.6   BUSINESS SEGMENTS

                         6.7.7   GEOGRAPHIC SEGMENTS

                         6.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.7.9   PRIMARY MARKET COMPETITORS

           6.8   ENZO BIOCHEM INC.

                         6.8.1   COMPANY OVERVIEW

                         6.8.2   COMPANY SNAPSHOT

                         6.8.3   OPERATING BUSINESS SEGMENTS

                         6.8.4   PRODUCT PORTFOLIO

                         6.8.5   BUSINESS PERFORMANCE

                         6.8.6   BUSINESS SEGMENTS

                         6.8.7   GEOGRAPHIC SEGMENTS

                         6.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.8.9   PRIMARY MARKET COMPETITORS

           6.9   DANAHER CORPORATION

                         6.9.1   COMPANY OVERVIEW

                         6.9.2   COMPANY SNAPSHOT

                         6.9.3   OPERATING BUSINESS SEGMENTS

                         6.9.4   PRODUCT PORTFOLIO

                         6.9.5   BUSINESS PERFORMANCE

                         6.9.6   BUSINESS SEGMENTS

                         6.9.7   GEOGRAPHIC SEGMENTS

                         6.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.9.9   PRIMARY MARKET COMPETITORS

           6.10   EUROFINS SCIENTIFIC SE

                         6.10.1   COMPANY OVERVIEW

                         6.10.2   COMPANY SNAPSHOT

                         6.10.3   OPERATING BUSINESS SEGMENTS

                         6.10.4   PRODUCT PORTFOLIO

                         6.10.5   BUSINESS PERFORMANCE

                         6.10.6   BUSINESS SEGMENTS

                         6.10.7   GEOGRAPHIC SEGMENTS

                         6.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.10.9   PRIMARY MARKET COMPETITORS

           6.11   CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

                         6.11.1   COMPANY OVERVIEW

                         6.11.2   COMPANY SNAPSHOT

                         6.11.3   OPERATING BUSINESS SEGMENTS

                         6.11.4   PRODUCT PORTFOLIO

                         6.11.5   BUSINESS PERFORMANCE

                         6.11.6   BUSINESS SEGMENTS

                         6.11.7   GEOGRAPHIC SEGMENTS

                         6.11.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.11.9   PRIMARY MARKET COMPETITORS

           6.12   LABCORP DRUG DEVELOPMENT.

                         6.12.1   COMPANY OVERVIEW

                         6.12.2   COMPANY SNAPSHOT

                         6.12.3   OPERATING BUSINESS SEGMENTS

                         6.12.4   PRODUCT PORTFOLIO

                         6.12.5   BUSINESS PERFORMANCE

                         6.12.6   BUSINESS SEGMENTS

                         6.12.7   GEOGRAPHIC SEGMENTS

                         6.12.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.12.9   PRIMARY MARKET COMPETITORS

           6.13   PROMEGA CORPORATION

                         6.13.1   COMPANY OVERVIEW

                         6.13.2   COMPANY SNAPSHOT

                         6.13.3   OPERATING BUSINESS SEGMENTS

                         6.13.4   PRODUCT PORTFOLIO

                         6.13.5   BUSINESS PERFORMANCE

                         6.13.6   BUSINESS SEGMENTS

                         6.13.7   GEOGRAPHIC SEGMENTS

                         6.13.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.13.9   PRIMARY MARKET COMPETITORS

           6.14   INSPHERO AG

                         6.14.1   COMPANY OVERVIEW

                         6.14.2   COMPANY SNAPSHOT

                         6.14.3   OPERATING BUSINESS SEGMENTS

                         6.14.4   PRODUCT PORTFOLIO

                         6.14.5   BUSINESS PERFORMANCE

                         6.14.6   BUSINESS SEGMENTS

                         6.14.7   GEOGRAPHIC SEGMENTS

                         6.14.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.14.9   PRIMARY MARKET COMPETITORS

           6.15   THERMO FISHER SCIENTIFIC INC.

                         6.15.1   COMPANY OVERVIEW

                         6.15.2   COMPANY SNAPSHOT

                         6.15.3   OPERATING BUSINESS SEGMENTS

                         6.15.4   PRODUCT PORTFOLIO

                         6.15.5   BUSINESS PERFORMANCE

                         6.15.6   BUSINESS SEGMENTS

                         6.15.7   GEOGRAPHIC SEGMENTS

                         6.15.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.15.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 2. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 3. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 4. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 5. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

TABLE 6. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 7. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 8. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 9. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 10. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 11. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 12. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 13. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 14. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 15. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

TABLE 16. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

TABLE 17. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

TABLE 18. INOTIV INC.: COMPANY SNAPSHOT

TABLE 19. INOTIV INC: OPERATING SEGMENTS

TABLE 20. INOTIV INC.: PR0DUCT PORTFOLIO

TABLE 21. INOTIV INC.: BUSINESS SEGMENT

TABLE 22. INOTIV INC.: GEOGRAPHIC SEGMENT

TABLE 23. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 24. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 25. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 26. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 27. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT

TABLE 28. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT

TABLE 29. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 30. EVOTEC A.G.: COMPANY SNAPSHOT

TABLE 31. EVOTEC A.G.: OPERATING SEGMENTS

TABLE 32. EVOTEC A.G.: PRODUCT PORTFOLIO

TABLE 33. EVOTEC A.G.: BUSINESS SEGMENT

TABLE 34. EVOTEC A.G.: GEOGRAPHIC SEGMENT

TABLE 35. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 36. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT

TABLE 37. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS

TABLE 38. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO

TABLE 39. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT

TABLE 40. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT

TABLE 41. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 42. WUXI APPTEC.: COMPANY SNAPSHOT

TABLE 43. WUXI APPTEC: OPERATING SEGMENTS

TABLE 44. WUXI APPTEC.: PR0DUCT PORTFOLIO

TABLE 45. WUXI APPTEC.: BUSINESS SEGMENT

TABLE 46. WUXI APPTEC.: GEOGRAPHIC SEGMENT

TABLE 47. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 48. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT

TABLE 49. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS

TABLE 50. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

TABLE 51. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT

TABLE 52. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT

TABLE 53. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 54. BRUKER: COMPANY SNAPSHOT

TABLE 55. BRUKER: OPERATING SEGMENTS

TABLE 56. BRUKER: PRODUCT PORTFOLIO

TABLE 57. BRUKER: BUSINESS SEGMENT

TABLE 58. BRUKER: GEOGRAPHIC SEGMENT

TABLE 59. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 60. PERKINELMER INC.: COMPANY SNAPSHOT

TABLE 61. PERKINELMER INC.: OPERATING SEGMENTS

TABLE 62. PERKINELMER INC.: PRODUCT PORTFOLIO

TABLE 63. PERKINELMER INC.: BUSINESS SEGMENT

TABLE 64. PERKINELMER INC.: GEOGRAPHIC SEGMENT

TABLE 65. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 66. ENZO BIOCHEM INC.: COMPANY SNAPSHOT

TABLE 67. ENZO BIOCHEM INC.: OPERATING SEGMENTS

TABLE 68. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO

TABLE 69. ENZO BIOCHEM INC.: BUSINESS SEGMENT

TABLE 70. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT

TABLE 71. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 72. DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 73. DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 74. DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 75. DANAHER CORPORATION: BUSINESS SEGMENT

TABLE 76. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 77. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT

TABLE 78. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO

TABLE 79. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT

TABLE 80. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 81. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT

TABLE 82. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS

TABLE 83. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO

TABLE 84. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT

TABLE 85. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT

TABLE 86. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 87. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT

TABLE 88. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS

TABLE 89. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO

TABLE 90. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT

TABLE 91. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT

TABLE 92. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS

TABLE 93. PROMEGA CORPORATION: COMPANY SNAPSHOT

TABLE 94. PROMEGA CORPORATION: PRODUCT PORTFOLIO

TABLE 95. INSPHERO AG: COMPANY SNAPSHOT

TABLE 96. INSPHERO AG: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 2. NORTH AMERICA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 3. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 4. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 5. NORTH AMERICA EARLY TOXICITY TESTING MARKET, BY COUNTRY, 2022-2030, MILLION USD

FIGURE 6. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 7. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 8. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 9. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 10. CANADA EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 11. CANADA IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 12. CANADA EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 13. CANADA EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 14. MEXICO EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 15. MEXICO IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD

FIGURE 16. MEXICO EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD

FIGURE 17. MEXICO EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD

FIGURE 18. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 19. INOTIV INC: PRIMARY MARKET COMPETITORS

FIGURE 20. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 21. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS

FIGURE 22. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)

FIGURE 23. EVOTEC A.G.: PRIMARY MARKET COMPETITORS

FIGURE 24. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)

FIGURE 25. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS

FIGURE 26. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 27. WUXI APPTEC: PRIMARY MARKET COMPETITORS

FIGURE 28. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)

FIGURE 29. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS

FIGURE 30. BRUKER: NET SALES, 2019–2021 ($MILLION)

FIGURE 31. BRUKER: PRIMARY MARKET COMPETITORS

FIGURE 32. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)

FIGURE 33. PERKINELMER INC.: PRIMARY MARKET COMPETITORS

FIGURE 34. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)

FIGURE 35. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS

FIGURE 36. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)

FIGURE 37. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 38. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 39. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS

FIGURE 40. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 41. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS

FIGURE 42. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)

FIGURE 43. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS

FIGURE 44. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS

FIGURE 45. INSPHERO AG: PRIMARY MARKET COMPETITORS

KEY PLAYERS

  • Inotiv Inc.

  • Bio-Rad Laboratories Inc

  • Evotec A.G. 

  • Agilent Technologies Inc

  • Wuxi Apptec

  • Bruker

  • Perkinelmer Inc.

  • Enzo Biochem Inc.

  • Danaher Corporation

  • Eurofins Scientific SE

  • Charles River Laboratories International, Inc.

  • Labcorp Drug Development.

  • Promega Corporation

  • Insphero AG

  • Thermo Fisher Scientific Inc.


Frequently Asked Questions
What will be the worth of North America early toxicity testing market by the end of 2030?

According to the report published by the Next Move Consulting, the North America early toxicity testing market business is expected to hit at $4.30 billion (USD) by 2030.

What are the leading companies in the North America early toxicity testing market?

The North America early toxicity testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG, and Thermo Fisher Scientific Inc.

What are the market segmentations and scope of the study for the North America early toxicity testing industry?

The North America early toxicity testing market share is segmented on the basis of technique, toxicity endpoint, and end user.

What factors are contributing to the expansion of the North America early toxicity testing market?

The factors contributing to the expansion of the North America early toxicity testing market are presence of major pharmaceutical companies, demand for personalized medicine, and technological advancements.

What factors are restraining the growth of the North America early toxicity testing market?

The factors restraining the growth of the North America early toxicity testing market are stringent regulatory compliance and financial constraints for smaller companies.